Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR6390 for CDK4-amplified recurrent or metastatic head and neck mucosal melanoma after standard treatment failure
ChiCTR2000035423Phase 2Recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dalpiciclib in mucosal melanoma (MM), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Objective response rate. Started Aug 2020; status: recruiting.
02
Drugs
dalpiciclib
03
Conditions
mucosal melanoma (MM)
Beyond the preview
Go deeper on ChiCTR2000035423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035423.